Cargando…

Study protocol for safety and efficacy of all-oral shortened regimens for multidrug-resistant tuberculosis: a multicenter randomized withdrawal trial and a single-arm trial [SEAL-MDR]

INTRODUCTION: The urgent need for new treatments for multidrug-resistant tuberculosis (MDR-TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) is evident. However, the classic randomized controlled trial (RCT) approach faces ethical and practical constraints, making alternative research...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Liang, Xiong, Juan, Wang, Haibo, Zhang, Peize, Yang, Qianting, Cai, Yi, Wang, Wenfei, Sun, Feng, Zhang, Xilin, Wang, Zhaoqin, Chen, Xinchun, Zhang, Wenhong, Deng, Guofang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683225/ https://www.ncbi.nlm.nih.gov/pubmed/38012543 http://dx.doi.org/10.1186/s12879-023-08644-8

Ejemplares similares

Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
por: Zhang, Peize, et al.
Publicado: (2022)

Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial
por: Weng, Taoping, et al.
Publicado: (2021)

Closure of pulmonary cavity of a multidrug-resistant tuberculosis patient with catheter insertion – A case report
por: Zhang, Peize, et al.
Publicado: (2020)

Factors Associated with Medical Follow-Up Adherence for Patients on All-Oral Regimen for Multidrug-Resistant Tuberculosis in Shenzhen, China
por: Li, Hui, et al.
Publicado: (2021)

Challenges Faced by Multidrug-Resistant Tuberculosis Patients in Three Financially Affluent Chinese Cities
por: Zhang, Peize, et al.
Publicado: (2020)

Steroid Avoidance or Withdrawal Regimens in Paediatric Kidney Transplantation: A Meta-Analysis of Randomised Controlled Trials
por: Zhang, Huanxi, et al.
Publicado: (2016)

Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial
por: Feng, Zhen, et al.
Publicado: (2023)

Pragmatic, randomized, blinded trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS)
por: Czynski, Adam, et al.
Publicado: (2023)

‘Z(S)-MDR-TB' versus ‘Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility
por: Zhang, Ying, et al.
Publicado: (2012)

A cross-sectional study: a breathomics based pulmonary tuberculosis detection method
por: Fu, Liang, et al.
Publicado: (2023)

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)

Allelic-Specific Regulation of xCT Expression Increases Susceptibility to Tuberculosis by Modulating microRNA-mRNA Interactions
por: Wang, Wenfei, et al.
Publicado: (2020)

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial
por: Lee, Myungsun, et al.
Publicado: (2019)

Novel strategies to prevent the development of multidrug resistance (MDR) in cancer
por: Wang, Jinglu, et al.
Publicado: (2017)

Comparison of characteristics and mortality in multidrug resistant (MDR) and non-MDR tuberculosis patients in China
por: Sun, Yanni, et al.
Publicado: (2015)

The effect of varying multidrug-resistence (MDR) definitions on rates of MDR gram-negative rods
por: Wolfensberger, Aline, et al.
Publicado: (2019)

Multidrug resistance (mdr) genes in human cancer.
por: Nooter, K., et al.
Publicado: (1991)

Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents
por: Feng, Senling, et al.
Publicado: (2020)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

Shortened tuberculosis treatment regimens: what is new?
por: Silva, Denise Rossato, et al.
Publicado: (2020)

Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusion
por: Cai, Yi, et al.
Publicado: (2022)

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan
por: Ali, Monadil H., et al.
Publicado: (2019)

The interaction of macrophages and CD8 T cells in bronchoalveolar lavage fluid is associated with latent tuberculosis infection
por: Yang, Qianting, et al.
Publicado: (2023)

Evaluation of the frequency of mutation genes in multidrug-resistant tuberculosis (MDR-TB) strains in Beijing, China
por: Liu, Y., et al.
Publicado: (2021)

Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
por: Grace, Angeline G, et al.
Publicado: (2019)

Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol
por: Gama, Elvis, et al.
Publicado: (2016)

Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
por: Mantefardo, Bahru, et al.
Publicado: (2021)

Treatment-shortening regimens for tuberculosis: updates and future priorities
por: Saluzzo, Francesca, et al.
Publicado: (2023)

Regulation and expression of multidrug resistance (MDR) transcripts in the intestinal epithelium
por: Li, M, et al.
Publicado: (1999)

Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies
por: Catalano, Alessia, et al.
Publicado: (2022)

Allogeneic Vγ9Vδ2 T-Cell Therapy Promotes Pulmonary Lesion Repair: An Open-Label, Single-Arm Pilot Study in Patients With Multidrug-Resistant Tuberculosis
por: Liang, Juan, et al.
Publicado: (2021)

Prevalence of crt and mdr-1 mutations in Plasmodium falciparum isolates from Grande Comore island after withdrawal of chloroquine
por: Huang, Bo, et al.
Publicado: (2016)

Issues in design and interpretation of MDR-TB clinical trials: report of the first Global MDR-TB Clinical Trials Landscape Meeting
por: Mitnick, Carole D, et al.
Publicado: (2015)

Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo
por: Wang, Gangyang, et al.
Publicado: (2022)

The MDR Upon Admission Score: Shortening Time to Initiation of Appropriate Antimicrobial Therapy in the Era of Resistance in the Community
por: Zilberman-Itskovich, Shani, et al.
Publicado: (2017)

Design real-time reversal of tumor multidrug resistance cleverly with shortened carbon nanotubes
por: Wu, Pingping, et al.
Publicado: (2014)

Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids
por: Limtrakul, Pornngarm, et al.
Publicado: (2004)

Functional Evidence of Multidrug Resistance Transporters (MDR) in Rodent Olfactory Epithelium
por: Molinas, Adrien, et al.
Publicado: (2012)

Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer
por: Reis, Mariana Alves, et al.
Publicado: (2020)

Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)
por: Sabur, Natasha F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n43tkbrb5h9pck5ik2dfhp93pk